UNSPSC 51453100: Anthelmintic pyrimidines

Anthelmintic drugs made from a family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms.

UNSPSC 51453100 Anthelmintic pyrimidines is a Class code that in practice encompasses pharmaceutical procurement by state and local governments, though recent opportunities show the code applied to a broader range of health-related products and services than the narrow chemical compound category the code name suggests. State and local issuing bodies are using this code to solicit naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing vehicles, direct-to-manufacturer pharmacy programs, and medical and first aid supplies for emergency response. The mix of issuing bodies includes county health departments (Seminole County, Florida), state health agencies (Texas HHS Commission), cities and municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participating jurisdictions). The scope reflects both acute emergency-response supplies and ongoing pharmaceutical inventory management for state and local health systems and public safety operations.

Recent activity is concentrated in Florida, Texas, Minnesota, and Oregon. Representative solicitations include Seminole County's IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually, due July 26, 2023), the City of Tampa's IFB for medical and first aid supplies including respiratory equipment, cardiac electrodes, and medical consumables for the Fire Department Rescue Division (169 line items, estimated contract value $700,000, with a small local business enterprise set-aside and 5 percent bid discount not to exceed $10,000, due March 13, 2026), Minnesota's MMCAP RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (proposals due March 26, 2026, with awards effective July 1, 2026), and the Texas HHS Commission's RFI on direct-to-manufacturer prescriptions for its Therapeutic Pharmacy Initiative (response deadline April 3, 2026). The code shows ongoing demand across state and local pharmacy benefit management, emergency medical supply chains, and community health initiatives, with recent activity also reflecting interest in direct manufacturer relationships and cost-containment strategies in pharmaceutical procurement.